Form 4 for AORT ARTIVION, INC.
Accepted 2026-06-15 11:28:57 ET · period of report 2026-06-11 · accession 0001628280-26-043059 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-15 11:28 | 2026-06-11 | AORT | GREEN ANDREW M | SVP, Regulatory, Quality | M - OptEx | $13.39 | +44.0K | 90.3K | +95% | +$589.1K |
| DMT | 2026-06-15 11:28 | 2026-06-11 | AORT | GREEN ANDREW M | SVP, Regulatory, Quality | S - Sale+OE | $20.70 | -44.0K | 60.3K | -42% | -$910.7K |
| DMT | 2026-06-15 11:28 | 2026-06-11 | AORT | GREEN ANDREW M | SVP, Regulatory, Quality | M - OptEx | $0.00 | -44.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-11 | M | A | 14,001 | $18.44 | 74,260 | D | — | — | (F1) The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. |
| 2 | Common | Common Stock | 2026-06-11 | S | D | 14,001 | $20.71 | 60,259 | D | — | — | (F1) The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. (F2) Reflects weighted average price. Range of prices were between $20.25 to $21.02. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2026-06-11 | M | A | 30,000 | $11.03 | 90,259 | D | — | — | (F1) The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. |
| 4 | Common | Common Stock | 2026-06-11 | S | D | 30,000 | $20.69 | 60,259 | D | — | — | (F1) The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. (F3) Reflects weighted average price. Range of prices were between $20.24 to $21.02. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 5 | Derivative | Stock Options (Right to buy) | 2026-06-11 | M | D | 14,001 | $0.00 | 0 | D | $18.44 · 2023-02-23 to 2029-02-23 | 14,001 Common Stock | (F1) The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. (F4) Stock options vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 23, 2023. |
| 6 | Derivative | Stock Options (Right to buy) | 2026-06-11 | M | D | 30,000 | $0.00 | 0 | D | $11.03 · 2023-11-08 to 2029-11-08 | 30,000 Common Stock | (F1) The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. (F5) Stock options vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023. |